Home Healthcare Healthcare Services Viral Vector Plasmid DNA Manufacturing Market

Viral Vector Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector-Type (AAV, Retrovirus, Adenovirus, Plasmids, Lentivirus, Others), By Workflow (Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}, Downstream {Purification, Fill-Finish}), By Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology, Research Applications), By End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), By Disease (Cancer, Genetic Disorders, Infectious Diseases, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Viral Vector Plasmid DNA Manufacturing Market, By Vector-Type 2022-2034 (USD MILLION/ Units)
    1. AAV
    2. Retrovirus
    3. Adenovirus
    4. Plasmids
    5. Lentivirus
    6. Others
  2. Viral Vector Plasmid DNA Manufacturing Market, By Workflow 2022-2034 (USD MILLION/ Units)
    1. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
    2. Downstream {Purification, Fill-Finish}
  3. Viral Vector Plasmid DNA Manufacturing Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Antisense and RNAi
    2. Gene Therapy
    3. Cell Therapy
    4. Vaccinology
    5. Research Applications
  4. Viral Vector Plasmid DNA Manufacturing Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical and Biopharmaceutical Companies
    2. Research Institutes
  5. Viral Vector Plasmid DNA Manufacturing Market, By Disease 2022-2034 (USD MILLION/ Units)
    1. Cancer
    2. Genetic Disorders
    3. Infectious Diseases
    4. Others
  6. Regional Viral Vector Plasmid DNA Manufacturing Market
    1. North America
      1. North America Viral Vector Plasmid DNA Manufacturing Market By Vector-Type 2022-2034 (USD MILLION/ Units)
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
      2. North America Viral Vector Plasmid DNA Manufacturing Market By Workflow 2022-2034 (USD MILLION/ Units)
        1. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        2. Downstream {Purification, Fill-Finish}
      3. North America Viral Vector Plasmid DNA Manufacturing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Antisense and RNAi
        2. Gene Therapy
        3. Cell Therapy
        4. Vaccinology
        5. Research Applications
      4. North America Viral Vector Plasmid DNA Manufacturing Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Research Institutes
      5. North America Viral Vector Plasmid DNA Manufacturing Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      6. U.S.
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      7. Canada
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
    2. Europe
      1. Europe Viral Vector Plasmid DNA Manufacturing Market By Vector-Type 2022-2034 (USD MILLION/ Units)
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
      2. Europe Viral Vector Plasmid DNA Manufacturing Market By Workflow 2022-2034 (USD MILLION/ Units)
        1. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        2. Downstream {Purification, Fill-Finish}
      3. Europe Viral Vector Plasmid DNA Manufacturing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Antisense and RNAi
        2. Gene Therapy
        3. Cell Therapy
        4. Vaccinology
        5. Research Applications
      4. Europe Viral Vector Plasmid DNA Manufacturing Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Research Institutes
      5. Europe Viral Vector Plasmid DNA Manufacturing Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      6. U.K.
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      7. Germany
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      8. France
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      9. Spain
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      10. Italy
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      11. Russia
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      12. Nordic
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      13. Benelux
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      14. Rest of Europe
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
    3. APAC
      1. APAC Viral Vector Plasmid DNA Manufacturing Market By Vector-Type 2022-2034 (USD MILLION/ Units)
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
      2. APAC Viral Vector Plasmid DNA Manufacturing Market By Workflow 2022-2034 (USD MILLION/ Units)
        1. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        2. Downstream {Purification, Fill-Finish}
      3. APAC Viral Vector Plasmid DNA Manufacturing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Antisense and RNAi
        2. Gene Therapy
        3. Cell Therapy
        4. Vaccinology
        5. Research Applications
      4. APAC Viral Vector Plasmid DNA Manufacturing Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Research Institutes
      5. APAC Viral Vector Plasmid DNA Manufacturing Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      6. China
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      7. Korea
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      8. Japan
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      9. India
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      10. Australia
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      11. Taiwan
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      12. South East Asia
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      13. Rest of Asia-Pacific
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
    4. Middle East and Africa
      1. Middle East and Africa Viral Vector Plasmid DNA Manufacturing Market By Vector-Type 2022-2034 (USD MILLION/ Units)
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
      2. Middle East and Africa Viral Vector Plasmid DNA Manufacturing Market By Workflow 2022-2034 (USD MILLION/ Units)
        1. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        2. Downstream {Purification, Fill-Finish}
      3. Middle East and Africa Viral Vector Plasmid DNA Manufacturing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Antisense and RNAi
        2. Gene Therapy
        3. Cell Therapy
        4. Vaccinology
        5. Research Applications
      4. Middle East and Africa Viral Vector Plasmid DNA Manufacturing Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Research Institutes
      5. Middle East and Africa Viral Vector Plasmid DNA Manufacturing Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      6. UAE
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      7. Turkey
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      8. Saudi Arabia
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      9. South Africa
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      10. Egypt
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      11. Nigeria
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      12. Rest of MEA
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
    5. LATAM
      1. LATAM Viral Vector Plasmid DNA Manufacturing Market By Vector-Type 2022-2034 (USD MILLION/ Units)
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
      2. LATAM Viral Vector Plasmid DNA Manufacturing Market By Workflow 2022-2034 (USD MILLION/ Units)
        1. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        2. Downstream {Purification, Fill-Finish}
      3. LATAM Viral Vector Plasmid DNA Manufacturing Market By Application 2022-2034 (USD MILLION/ Units)
        1. Antisense and RNAi
        2. Gene Therapy
        3. Cell Therapy
        4. Vaccinology
        5. Research Applications
      4. LATAM Viral Vector Plasmid DNA Manufacturing Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Research Institutes
      5. LATAM Viral Vector Plasmid DNA Manufacturing Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      6. Brazil
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      7. Mexico
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      8. Argentina
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      9. Chile
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      10. Colombia
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
      11. Rest of LATAM
        1. AAV
        2. Retrovirus
        3. Adenovirus
        4. Plasmids
        5. Lentivirus
        6. Others
        7. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
        8. Downstream {Purification, Fill-Finish}
        9. Antisense and RNAi
        10. Gene Therapy
        11. Cell Therapy
        12. Vaccinology
        13. Research Applications
        14. Pharmaceutical and Biopharmaceutical Companies
        15. Research Institutes
        16. Cancer
        17. Genetic Disorders
        18. Infectious Diseases
        19. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.